Petrovax to join the session “New Laws in Regulating the Circulation of Medicinal Products within the Eurasian Economic Union” as a partner

Petrovax will act as a partner in a panel discussion dedicated to regulating the circulation of medicinal products within the EAEU, to be held as part of the 6th All-Russian GMP Conference with International Participants on 23 September 2021.  

Petrovax is a full-cycle biopharmaceutical company  with 25 years of successful experience. Today, it is a leading developer and manufacturer of original medicines and vaccines, which is included in the TOP-5 immunobiological manufacturers in Russia. The company’s product portfolio includes its own original pharmaceutical products and vaccines, localized medicinal products, as well as generics and dietary supplements. Petrovax has its own research infrastructure and over 20 patents for new molecules and manufacturing technologies. The company’s partners are international leaders of the pharmaceutical market, such as Pfizer, Abbott, Boehringer Ingelheim.  

Located in the Moscow Region, the pharmaceutical production complex for the manufacture of APIs and finished dosage forms operates in full compliance with Russian and international GMP standards. The enterprise’s capacities allow for the annual production of 160 million doses of pharmaceutical products. 

The company is the largest exporter of original medicines and vaccines in Russia. The company exports products to 12 countries, including the countries of the EAEU and the EU. 

In 2021, Petrovax joined the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union. The Association was registered in 2012, and today it includes the leading full-cycle pharmaceutical companies. This organization contributes to implementing and improving the principles of good manufacturing practice and developing the EAEU pharmaceutical market in general.  

The panel discussion “New Laws in Regulating the Circulation of Medicinal Products within the Eurasian Economic Union”, supported by Petrovax, will raise the most pressing issues of integration within the single pharmaceutical EAEU market. The current changes in regulatory legal acts, new documents (level 3) and the Pharmacopoeia of the Eurasian Economic Union will be under review.